VEGF pathway inhibition potentiates PARP inhibitor efficacy …
2021年11月6日 · Poly ADP-ribose polymerase inhibitors (PARPi) have transformed ovarian cancer (OC) treatment, primarily for tumours deficient in homologous recombination repair. …
Role of PARP and TRPM2 in VEGF Inhibitor‐Induced Vascular …
2023年2月20日 · We investigated whether PARP/TRPM2 plays a role in VEGFi‐induced vascular dysfunction and whether PARP inhibition ameliorates the vasculopathy associated with VEGF …
Emergence of cyclic hypoxia and the impact of PARP inhibitors
2024年10月22日 · The insight into the role of VEGF and cytokine signaling in controlling hypoxia cycles, as well as the predictive assessment of the therapeutic effects of PARP inhibitors, …
PARP抑制剂与免疫治疗协同增效抗癌，已在乳腺癌、胃癌等6种癌 …
在临床前及早期临床研究中发现聚腺苷二磷酸核糖聚合酶 (PARP)抑制剂就是这类药物，可与免疫治疗起到相互协同的作用。 通过抑制DNA修复产生DNA损伤，增加肿瘤突变负荷，成为更具 …
Regulation of poly ADP-ribosylation of VEGF by an interplay
2020年5月30日 · The data presented in this manuscript suggest that PARP-16 catalysis the priming mono ADP-ribosylation of VEGF which is a prerequisite for poly ADP-ribosylation of …
PARP抑制剂联合抗血管生成药：多类型卵巢癌获益，这种新疗法 …
2020年5月，美国食品药品监督管理局（Food and Drug Administration, FDA）批准PARP抑制剂奥拉帕利与抗血管生成抑制剂贝伐珠单抗联合，用于同源重组缺陷（HRD）阳性晚期卵巢癌的一 …
Role of PARP and TRPM2 in VEGF Inhibitor-Induced Vascular
Underlying molecular mechanisms are unclear, but PARP-regulated transient receptor potential cation channel, subfamily M, member 2 (TRPM2), a redox-sensitive calcium channel, may be …
Dual inhibition of VEGF and PARP suppresses KRAS-mutant ... - PubMed
In the present study, we investigated a combination approach of bevacizumab + olaparib in KRAS-mut CRC in a preclinical setting. The combined therapy effectively prevented tumor …
VEGF pathway inhibition potentiates PARP inhibitor efficacy in …
2021年11月6日 · Poly ADP-ribose polymerase inhibitors (PARPi) have transformed ovarian cancer (OC) treatment, primarily for tumours deficient in homologous recombination repair. …
Dual inhibition of VEGF and PARP suppresses KRAS-mutant …
2020年9月1日 · In the present study, we investigated a combination approach of bevacizumab + olaparib in KRAS-mut CRC in a preclinical setting. The combined therapy effectively prevented …
- 某些结果已被删除